Utilities Registry

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Valuation

Population

Condition

Viewing 21 - 30 of 44 results

Title	Year(s) of data collection	Valuation Method	Country	Condition
Selection of mental health health state utilities (Denee T et al., J Affect Disord. 2023. doi:10.1016/j.jad.2022.12.135)	2019	EQ-5D-5L	United Kingdom of Great Britain and Northern Ireland	Depression - caregivers
DOI 10.7910/DVN/QNA5ZF Author(s) Registry, Utilities Description Health state utilities for mental health conditions Sample Characteristics 99 carers of individuals with symptomatic treatment-resistant depression or in remission post-TRD
Title Selection of oncology health state utilities (Clavo B et al., Int J Environ Res Public Health. 2023. doi:10.3390/ijerph20021479)	Year(s) of data collection 2019 - 2022	Valuation Method EQ-5D-5L	Country Spain	Condition Symptomatic Cancer Survivor
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 26 patients with persistent or refractory side effects of cancer treatments to investigate the effects of ozone treatment
Title Selection of oncology health state utilities (Cooper OAE et al., Pharmacoecon Open. 2023. doi:10.1007/s41669-023-00392-4)	Year(s) of data collection 2021	Valuation Method EQ-5D-5L	Country United Kingdom of Great Britain and Northern Ireland	Condition Invasive bladder cancer
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 202 individuals from UK general public
Title Selection of oncology health state utilities (Yang M et al., Value Health. 2023. doi:10.1016/j.jval.2023.02.00)	Year(s) of data collection 2016 - 2021	Valuation Method EQ-5D-5L	Country Austria, Belgium, China, France, Germany, Israel, Italy, Japan, Korea (Republic of), Netherlands, Poland, Spain, Switzerland, Taiwan (Province of China), United States of America	Condition Lung cancer
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 273 patients with non-small cell lung cancer harboring MET exon 14 skipping treated with tepotinib
Title Selection of neurological disease health state utilities (Gebrehiwet P et al., J Med Econ. 2023. doi:10.1080/13696998.2023.2192588)	Year(s) of data collection 2017 - 2019	Valuation Method EQ-5D-5L	Country Australia, Canada, Ireland, Netherlands, Spain, United States of America	Condition Amyotrophic lateral sclerosis
DOI 10.7910/DVN/VJSSSX Author(s) Registry, Utilities Description Health state utilities for neurological disease conditions Sample Characteristics 456 participants with clinical trial data from FORTITUDE-ALS that evaluated reldesemtiv versus placebo in patients with ALS
Title Selection of neurological disease health state utilities (Looby A et al., J Med Econ. 2023. doi:10.1080/13696998.2023.2189395)	Year(s) of data collection 2022	Valuation Method EQ-5D-5L	Country United Kingdom of Great Britain and Northern Ireland	Condition Spinal cord injury
DOI 10.7910/DVN/VJSSSX Author(s) Registry, Utilities Description Health state utilities for neurological disease conditions Sample Characteristics A cohort of 57 patients with spinal cord injury
Title Selection of autoimmune disease health state utilities (Armuzzi A et al., BMC Gastroenterol. 2023. doi:10.1186/s12876-023-02640-7)	Year(s) of data collection 2020 - 2021	Valuation Method EQ-5D-5L	Country France, Germany, Italy, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Ulcerative colitis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics a point-in-time survey of 164 matched patients treated with tofacitinib
Title Selection of autoimmune disease health state utilities (Saccà F et al., J Neurol. 2023. doi:10.1007/s00415-022-11517-w)	Year(s) of data collection 2018 - 2020	Valuation Method EQ-5D-5L	Country Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 167 participants in phase 3 RCT of efgartigimod, ADAPT trial
Title Selection of orthopedic and musculoskeletal health state utilities (Zhou AK et al., Eur J Orthop Surg Traumatol. 2023. doi:10.1007/s00590-022-03204-3)	Year(s) of data collection 2014 - 2021	Valuation Method EQ-5D-5L	Country United Kingdom of Great Britain and Northern Ireland	Condition Open talus fractures
DOI 10.7910/DVN/VR4XYO Author(s) Registry, Utilities Description Health state utilities for orthopedic and musculoskeletal conditions Sample Characteristics 14 participants from the review of electronic hospital records, cohort
Title Selection of orthopedic and musculoskeletal health state utilities (Eguchi Y et al., Pain Ther. 2023. doi:10.1007/s40122-022-00472-z)	Year(s) of data collection 2021 - 2022	Valuation Method EQ-5D-5L	Country Japan	Condition Lumbar spinal stenosis with low back pain
DOI 10.7910/DVN/VR4XYO Author(s) Registry, Utilities Description Health state utilities for orthopedic and musculoskeletal conditions Sample Characteristics A multicenter, randomized, active-controlled, open-label trial of 64 patients diagnosed with LSS by MRI to examine the clinical efficacy of neurotropin for lumbar spinal stenosis with low back pain

← Previous results Next results →